The fantastic Pink Floyd songs “Dogs”1 and “The Dogs of War”2 stalk the same corporate archetype. Across “Dogs”, a smarmy businessman ages from a hungry young man into an isolated old man; the unnamed businessman works in the shadows until the results of his career close their jaws around his throat. Within “The Dogs of War”, unscrupulous arms dealers have already been bred by an industry of mercenaries. Between the two songs, one method repeats: move silently, earn trust, and protect the corporate machine. If that corporate machine is threatened, the businessman instinctively knows “that everyone’s expendable” while the arms dealers understand that “discovery is to be disowned”.3
You’ve got to be able to pick out the easy meat with your eyes closed
And then moving in silently, down wind and out of sight,
You’ve got to strike when the moment is right without thinking— Pink Floyd, “Dogs”
Roger Waters wrote the lyrics to “Dogs”. After Waters left Pink Floyd, David Gilmour and Anthony Moore wrote “The Dogs of War”. Within this piece, Scott Sperling and Marc Casper, both of Thermo Fisher Scientific (Thermo Fisher), aren’t literal song characters; their public corporate biographies fuse into one character amalgamation, and that corporate archetype inhabits two Board seats at Mass General Brigham (MGB). Across the two songs, authorship changes, but the insatiable appetite for personal and corporate destruction keeps feeding those dogs. Inside “Dogs of MGB”, that amalgamation lets the documentary record carry the comparison without pretending that metaphor supplies evidence.
Dogs of war and men of hate
With no cause, we don’t discriminate
Discovery is to be disowned
Our currency is flesh and bone
Hell opened up and put on sale
Gather ’round and haggle
For hard cash, we will lie and deceive
Even our masters don’t know the webs we weave— Pink Floyd, “The Dogs of War”
As Chairman of the Board of Directors of Mass General Brigham (MGB), Scott Sperling leads MGB’s Board while serving as Independent Lead Director of Thermo Fisher Scientific (Thermo Fisher). As a Director on MGB’s Board, Marc Casper helps govern MGB while leading Thermo Fisher as Chairman of the Board of Directors and Chief Executive Officer (CEO). Sperling climbed through Thomas H. Lee Partners (THL), a private equity firm, and Fisher Scientific. Inside Thermo Electron Corporation, Casper scaled the operating ladder. Sperling and Casper now stalk the same nonprofit health care corporation’s Board, a recurring pattern of men from Thermo Fisher and its predecessors, while guarding a separate corporate henhouse.4
By the middle of “Dogs”, the businessman works “on points for style”, and the 2026 proxy statement of Thermo Fisher Scientific (Thermo Fisher) converts style into corporate arithmetic. Within Thermo Fisher, Marc Casper holds the offices of Chairman of the Board of Directors and Chief Executive Officer (CEO); the summary compensation table records $79,923,350 in 2025 total compensation, including $65,730,211 in stock-award accounting value, while a conditional retention award drives $57.7 million of grant-date fair value and would deliver no earned shares before 2033. Within Thermo Fisher, Scott Sperling holds the office of Independent Lead Director and serves as a member of the Compensation Committee; the same table records $437,728 in 2025 director compensation plus a separate $48,000 annual Thermo Fisher legacy retirement benefit. Sperling recommended Casper’s retention award through the Compensation Committee. Sperling signed the committee letter defending that award.5
In “Dogs”, the businessman “put[s] the knife in” after he’s “trusted by the people that [he lies] to”. The governance record of Mass General Brigham (MGB) sharpens that lyric into an institutional question: within MGB, Scott Sperling holds the office of Chairman of the Board of Directors, while Marc Casper serves as a Director. Within Thermo Fisher Scientific (Thermo Fisher), Marc Casper holds the offices of Chairman of the Board of Directors and Chief Executive Officer (CEO), while Scott Sperling holds the office of Independent Lead Director. Across the two corporations, the same men occupy both Boards of Directors: Sperling holds the office of Chairman at MGB, while Casper holds the office of Chairman at Thermo Fisher. Inside MGB’s fiscal year 2024 (FY2024) Form 990, MGB reports a “business relationship” between Casper and Sperling without describing that relationship. Within MGB, Anne Klibanski holds the offices of President and CEO and also serves as a Director on MGB’s Board of Directors. Under MGB’s conflict process, MGB assigns the review of Directors’ disclosures to Sperling in his capacity as Chairman of the Board of Directors and to Klibanski in her capacity as President and CEO, with assistance from MGB’s Office of the General Counsel. MGB’s disclosure requirement reaches Casper, Sperling, and Klibanski in their capacities as Directors. Inside MGB’s published conflict architecture, Sperling occupies two institutionally distinct positions: he’s one of the two Directors in the reported business relationship and the Chairman assigned to review Directors’ disclosures. MGB’s return supplies no matter-specific record showing review of the Casper-Sperling relationship and identifies no alternate reviewer for a disclosure involving the Chairman. “Dogs” sheaths the knife in metaphor; MGB’s public record places the song’s trust beside the reported relationship between Casper and Sperling, Sperling’s office as Chairman, and Form 990’s silence concerning an alternate reviewer for a disclosure involving the Chairman.6
Within the corporate structure imagined by those two songs, Scott Sperling and Marc Casper inhabit the Board of Mass General Brigham (MGB); the absence of published review and recusal records leaves the wolf in sheep’s clothing hypothetical and the governance effect of dual service untested across purchasing, licensing, commercialization, conflicts, and recusals, so MGB should unseal the records and let patients, workers, and researchers trace the corporate relationships.
Mass General Brigham (MGB) seats Scott Sperling and Marc Casper among twenty-six directors; Thermo Fisher Scientific (Thermo Fisher) seats Sperling and Casper on its Board. MGB’s pension plan summary assigns the Board responsibility for selecting the professional managers who assist the MGB ERISA Master Trust; MGB’s audited financial statements assign pension oversight to the Board Investment Committee (BIC).7 MGB’s public disclosures stop before a current authoritative BIC roster, minutes, conflict disclosures, and recusal records; the public therefore can’t test individual committee conduct.
If the purchase and sale of pipette tips enveloped the entirety of the transaction records, dual Board occupations would still demand conflict records because, in these intertwined relationships, the public record reaches far beyond simple pipette tips. Under the Mass General Brigham (MGB) and Thermo Fisher Scientific (Thermo Fisher) organizational umbrellas, my working index tracks thirty-seven separately bounded connectors or relationship families. Within that index, four directions drive the pattern: MGB-family science feeds Thermo Fisher products; Thermo Fisher products penetrate MGB-family operations; federal and clinical infrastructure knots both; and MGB-linked commercialization or institutional promotion funnels access and visibility toward Thermo Fisher. For every connector, “The 37 Connectors” pins down its legal entity, date, direction, and acquisition posture; the number measures recurrence rather than pretending thirty-seven distinct records are thirty-seven contracts, payments, conflicts, or current relationships.8 Across the working index, those thirty-seven connectors force a governance demand: MGB should publish the review path for every indexed relationship — including the absence of review — together with any surviving conflict, recusal, and approval records.
Across successive acquisitions, earlier connections have hardened into present patterns of overlapping authority. Thermo Fisher Scientific (Thermo Fisher) didn’t originate every relationship beneath its corporate umbrella; acquisitions have absorbed earlier ties and converted them into present-day corporate webs. “The Dogs of War” tightens that acquisition web: “even our masters don’t know the webs we weave”.
Discovery Is to Be Disowned
Inside “The Dogs of War”, “discovery” means exposure, not invention. Once outsiders expose an inside operative, the corporate machine denies the colleague and cuts him — it “disowns” him — from the corporate system. Against that chugging machinery of deniability, the records below fasten work to suppliers, rights to licensors, and products to sellers; the same public trail often cuts off before approval, transfer, and allocation terms.
Inside the Laboratory of Computer Science at Massachusetts General Hospital (MGH), Neil Pappalardo and Curt Marble created the Massachusetts General Hospital Utility Multi-Programming System (MUMPS) in 1967 to support a large-scale hospital information system; from its first line of code, MUMPS targeted hospital infrastructure. Under Octo Barnett, MGH kept the language in the public domain so broader use could drive computer science forward across health care. By the early 1970s, hospitals throughout the industry had deployed MUMPS.9
Through the public-domain release, Massachusetts General Hospital (MGH) let health care institutions use, adapt, and share a hospital tool without paying a private owner. In that decision, MGH treated institutional invention as health care infrastructure rather than inventory. Oh, times have changed!
Work Becomes Product
At MEDITECH, Phillip “Terry” Ragon learned the Massachusetts General Hospital Utility Multi-Programming System (MUMPS) language and later built InterSystems Corporation (InterSystems) around a database coded in the language born at Massachusetts General Hospital (MGH). Within Mass General Brigham (MGB), Phillip “Terry” Ragon holds the office of Director. MGB’s fiscal year 2024 (FY2024) return records a $709,351 products-and-services transaction with InterSystems.10 By design, the code left MGH; private enterprise converted its public value into proprietary commercial value. Decades later, InterSystems’ private owner entered MGB’s Board while his company appeared in MGB’s related-party vendor disclosures.
At the end of “Dogs”, the archetypical businessman is “dying of cancer”; inside the record of Massachusetts General Hospital (MGH), cancer drives the next hinge between public mission and private product. By December 2002, MGH Cancer Center researchers had supplied C. elegans ribonucleic acid (RNA) used to generate an Invitrogen pre-made complementary deoxyribonucleic acid (cDNA) library. Inside the same manual, patent rights licensed by MGH and Johns Hopkins University (Johns Hopkins) covered the Reverse Two-Hybrid system; inside a separate manual, MGH owned U.S. Patent 5,580,736 and licensed it to Invitrogen for the Interaction Trap system.11
On February 3, 2014, Thermo Fisher Scientific (Thermo Fisher) completed its acquisition of Life Technologies Corporation; the acquisition pulled Invitrogen into the present corporate family. The acquisition fixes the current chain of custody. Under the Thermo Fisher umbrella, biological material originating at Massachusetts General Hospital (MGH) fed an Invitrogen complementary deoxyribonucleic acid (cDNA) library; patent rights licensed by MGH and Johns Hopkins University (Johns Hopkins) covered the Reverse Two-Hybrid system, while MGH-owned patent rights anchored the Interaction Trap system.
Between the Massachusetts General Hospital Utility Multi-Programming System (MUMPS) and Invitrogen, work from Massachusetts General Hospital (MGH) — some of it predating the formation of Mass General Brigham (MGB) — moved outward into private products; through separate transactions, MGB-family institutions later bought products and services from the InterSystems Corporation and Thermo Fisher Scientific (Thermo Fisher) corporate families, and those records preserve two recurrent directions without closing a loop around the same product. Inside the public manuals, readers can trace MGH-origin inputs into corporate products; across the public sources I’ve reviewed, the trail stops before the agreements allocating ownership, transfer, and compensation. Beyond the product manuals, employment status, assignment terms, consideration, inventor shares, and laboratory allocations disappear from public view.
In “Dogs”, betrayal begins “when they turn their backs on you”; in “The Dogs of War”, the “invisible transfers, long distance calls” signify the working end of that same betrayal, and when the documents are “signed [and] sealed, [they] deliver oblivion”.
At Brigham and Women’s Hospital (BWH), science later moved through Exosome Diagnostics and Bio-Techne into an exclusive development-and-commercialization arrangement with Thermo Fisher Scientific (Thermo Fisher); One Lambda, a Thermo Fisher business, now offers an assay incorporating the ExoTRU technology.12
As health care images, “dying of cancer” and “flesh and bone” expose the stakes: biological material, scientific labor, and clinical expertise feed commercial chains. Behind the public endpoints, executed licenses, approval records, inventor distributions, and laboratory allocations would lay bare the economics. Across the reviewed sources, the public trail stops before the governing records.
Moving In Silently
On October 18, 2002, Thermo Electron Corporation (Thermo Electron) announced a research collaboration with Partners HealthCare (Partners) at the new Proteomics Facility at the Harvard-Partners Center for Genetics and Genomics; Thermo Electron committed four integrated ProteomeX systems and placed one of its applications scientists “in residence”, working directly with researchers and collecting feedback for corporate product development.13
Across the disclosed arrangement, “moving in silently” turns into institutional motion rather than an allegation of concealment: Partners HealthCare (Partners) opened its research setting, premier clinical-research community, and direct product feedback to Thermo Electron Corporation (Thermo Electron); Thermo Electron embedded the machines and scientist. Through that exchange, work from a predecessor of Mass General Brigham (MGB) flowed outward while a corporate scientist moved inward. The inside work went out that door; the outside scientist went in through that same door.
Through its own announcement, Thermo Electron Corporation (Thermo Electron) advertised both gains and priced neither contribution.
By October 26, 2004, Thermo Electron Corporation (Thermo Electron) and Massachusetts General Hospital (MGH) had launched the Biomarker Research Initiatives in Mass Spectrometry (BRIMS) Center, a joint biomarker-research facility in Cambridge, Massachusetts. Inside BRIMS, MGH fed basic-science and clinical expertise, biostatistics, and validation assistance into the joint work; Thermo Electron supplied personnel, mass spectrometers, laboratory instruments, software, services, and the Cambridge facility. As President of Thermo Electron’s Life and Laboratory Sciences segment, Marc Casper framed the work as a step from commercializing technology platforms toward using them to characterize disease.14
By July 2007, the corporate yield of Biomarker Research Initiatives in Mass Spectrometry (BRIMS) had surfaced. Chemical & Engineering News called BRIMS a Thermo Fisher Scientific (Thermo Fisher) “technology showcase” staffed by company employees. Inside BRIMS, Thermo Fisher employees developed Sieve software, which Thermo Fisher launched as a product; after the relationship with Massachusetts General Hospital (MGH) ended, the center collaborated on new protein-labeling reagents. “The Dogs of War” supplies BRIMS with an epitaph: “Well, winners can lose, and things can get strained but whatever you change, you know the dogs remain.” Thermo Fisher’s product gain is public; MGH’s bargain isn’t.15
The Osmotic Membrane
Across both collaborations, science and clinical expertise from Massachusetts General Hospital (MGH) and Partners HealthCare (Partners) fed product development at Thermo Electron Corporation (Thermo Electron), while Thermo Electron personnel and instruments penetrated the predecessor research architecture of Mass General Brigham (MGB). Inside that shared architecture, vendor and collaborator fused; the membrane turned osmotic. Through the membrane, hospital expertise and feedback flowed toward corporate product development while ownership, compensation, and value-allocation terms didn’t flow back into public view.
After the instruments came the product transactions. The fiscal year 2009 (FY2009) tax return of Brigham and Women’s Hospital (BWH) records an $11,235,649 products transaction with Thermo Fisher Scientific (Thermo Fisher). Partners HealthCare (Partners) parent returns later record $15,164,678 in fiscal year 2012 (FY2012), $17,010,411 in fiscal year 2013 (FY2013), and $24,219,046 in fiscal year 2014 (FY2014).16 Across separate filing periods and entities, the figures establish repeated purchasing but may capture only a sampling of the transactions. Because Forms 990 don’t function as vendor ledgers, consolidation, allocation, and reimbursement mechanics block a defensible grand total without the underlying records.
Across laboratories in the Mass General Brigham (MGB) family, MGB operations absorbed Thermo Fisher Scientific (Thermo Fisher) platforms into routine infrastructure: BRAHMS KRYPTOR analyzers in a Brigham and Women’s Hospital (BWH) research laboratory, TaqPath in BWH’s COVID-19 testing workflow, TaqMan and Applied Biosystems systems in system cores, and an Orbitrap Astral at Massachusetts General Hospital (MGH). By November 2025, Fisher Scientific advertised a new agreement. Under that agreement, its channel became MGB’s preferred provider of research products and funneled ordering through MGB Marketplace.17
Across these interwoven records, corporate commingling means documented institutional interpenetration between Mass General Brigham (MGB) and Thermo Fisher Scientific (Thermo Fisher): MGB work exits while Thermo Fisher personnel and platforms enter; purchasing, trials, licenses, commercialization, and Board governance bind both institutional families at repeated points through time.
At the first documented collaboration between predecessors in the Mass General Brigham (MGB) and Thermo Fisher Scientific (Thermo Fisher) families, four ProteomeX systems, one resident scientist, and direct product feedback had already exceeded a generic machine sale. Across more than twenty-five years, thirty-seven bounded connectors defeat any description of the relationship as isolated; set beside the present double occupation of MGB’s Board, that density demands records. From one resident scientist to a preferred procurement channel, the data points outgrow metaphor: hospital science moved out, Thermo Fisher systems and personnel moved in, and repeated purchasing tightened the bond.
The Web Widens
The federal audits of Partners HealthCare (Partners) pull the predecessor families of Mass General Brigham (MGB) and Thermo Fisher Scientific (Thermo Fisher) into the same tables. During fiscal years 2013 (FY2013) and 2014 (FY2014), the audits list Fisher BioServices as a pass-through sponsor to Massachusetts General Hospital (MGH) under a contract that the National Institutes of Health (NIH) identifies as the National Institute of Allergy and Infectious Diseases (NIAID) AIDS Reagent Program. During fiscal years 2014 (FY2014), 2015 (FY2015), and 2017 (FY2017), the audits list PPD Development as a federal pass-through sponsor involving Brigham and Women’s Hospital (BWH) or Partners; Thermo Fisher later absorbed PPD in a $17.4 billion acquisition completed on December 8, 2021, pulling PPD’s earlier relationships with the MGB family under Thermo Fisher’s present corporate umbrella without recasting Thermo Fisher as the historical counterparty.18
Thermo Fisher Scientific (Thermo Fisher) tightened the mesh again on August 14, 2023, when its $912.5 million acquisition absorbed CorEvitas; the Neuroimmunology Clinic at Massachusetts General Hospital (MGH) currently enrolls patients in the Synergy of Prospective Health and Experimental Research for Emerging Solutions in Neuromyelitis Optica Spectrum Disorder (SPHERES) registry with the Guthy-Jackson Charitable Foundation and CorEvitas, while the public page leaves funding, data rights, contract terms, and MGH’s participation date undisclosed.19
Through six records, ClinicalTrials.gov pins PPD Development to a sponsor or collaborator role and pairs Massachusetts General Hospital (MGH) or Brigham and Women’s Hospital (BWH) in the same study record. Inside the Synergy of Prospective Health and Experimental Research for Emerging Solutions in Neuromyelitis Optica Spectrum Disorder (SPHERES) registry, MGH enrolls patients alongside CorEvitas and publicly identifies CorEvitas as a registry partner. Beyond laboratory products, the present umbrella of Thermo Fisher Scientific (Thermo Fisher) reaches into the corporate architecture organizing clinical studies and a live patient registry; the public sources document that reach while leaving hospital selection, payment, data ownership, and bilateral contract terms unanswered.20
In “The Dogs of War”, the web outgrows even its masters; between the Thermo Fisher Scientific (Thermo Fisher) and Mass General Brigham (MGB) families, acquisitions let Thermo Fisher absorb studies and registries that began under earlier owners, and across these dates, the record places payments to the Thermo Fisher family beside separate flows of scientific input, clinical access, and institutional visibility from the MGB family, while employees, inventors, laboratories, patients, and plan participants still lack a complete ledger.
The dogs of war don’t negotiate
The dogs of war won’t capitulate,
They will take and you will give,
And you must die so that they may live— Pink Floyd, “The Dogs of War”
The Masters in Marble Halls
As of September 30, 2025, Mass General Brigham (MGB) reported $11.586 billion in pension-plan assets. Separately, MGB’s central investment pools held $18.258 billion in net assets. Although the figures describe different pools and must remain separate, both answer to MGB’s Board Investment Committee (BIC).21
The Cash Balance Program of Mass General Brigham (MGB) assigns its Board responsibility for selecting the Master Trust’s professional investment managers; Scott Sperling holds the office of Chairman of the Board of Directors, while Marc Casper serves as a Director. MGB’s audited statements separately assign pension asset oversight and external manager selection to the Board Investment Committee (BIC). Between those two descriptions, the public record stops before the delegation, appointment, and removal chain connecting Board authority to BIC action.
Around an Employee Retirement Income Security Act of 1974 (ERISA) trust holding nearly $11.6 billion for workers and retirees, Mass General Brigham (MGB) publishes the assets while the governing people and decisions remain in shadow: the current Board Investment Committee (BIC) roster, charter, delegations, minutes, manager-selection records, conflicts, recusals, and fee schedules; that opacity belongs in no administrative footnote.
The files of Thermo Fisher Scientific (Thermo Fisher) set a disclosure standard: the 2008 proxy disclosed that the Fisher Scientific International Inc. Defined Benefit Master Trust had committed $2.5 million to Monitor Clipper Fund I in 1997 and $2.1 million to Fund II in 2003. After both commitments, Michael Bell began serving as a Director on Thermo Fisher’s Board of Directors in 2007; within Monitor Clipper Partners, Bell held the office of Managing Director and an ownership interest in the firm. Even then, the proxy exposed Monitor Clipper Partners’ approximate 2% management fee, 20% carried interest, and Bell’s indirect participation in that compensation.22
Inside Thermo Fisher Scientific (Thermo Fisher), Michael Bell began serving as a Director in 2007 after both fund commitments and the Fisher Scientific merger; inside Monitor Clipper Partners, Bell already held the office of Managing Director and an ownership interest in the firm, so the chronology can’t erase the disclosure standard. Inside its own archive, Thermo Fisher published the trust, funds, commitments, fees, carry, and Bell’s indirect financial participation once Bell became a sitting Director. Against that demonstrated standard, the public record of Mass General Brigham (MGB) falls short.
The Government Master
Within the Pink Floyd framework, the Employee Benefits Security Administration (EBSA) takes the role of government “master”. Under federal law, EBSA administers and enforces the Employee Retirement Income Security Act of 1974 (ERISA), investigates compliance, and can compel records. Through investigations and subpoenas, EBSA can pull a web hidden from workers and public view into federal hands.23
Inside “The Dogs of War”, there’s “hollow laughter in marble halls” while the government “master” misses “the webs we weave”.
Inside Mass General Brigham (MGB), workers meet silence where a Board Investment Committee (BIC) roster and minutes should stand, and across a health care system, the moral bargain must reverse the song: people shouldn’t feed the institution; the institution should sustain its patients, workers, and researchers.
Mass General Brigham (MGB) should publish the Board Investment Committee (BIC) charter, roster, delegations, minutes, manager selections, fees, conflicts, and recusals; across that silence, the dogs inhabit the Board’s “marble halls”, while opacity inhibits public scrutiny.
And when you lose control,
You’ll reap the harvest you have sown
And as the fear grows,
The bad blood slows and turns to stone
And it’s too late to lose the weight
You used to need to throw around
So have a good drown, as you go down,
All alone, dragged down by the stone
Source Notes
- Pink Floyd, Animals; Apple Music, “Dogs” lyric and songwriting credits. Pink Floyd’s official album page identifies “Dogs” as an earlier Roger Waters composition developed within Waters’s expanded Animals concept; the licensed Apple Music page supplies the track’s lyric text and credits. ↩︎
- Pink Floyd, A Momentary Lapse of Reason; Apple Music, “The Dogs of War” lyric and songwriting credits. Pink Floyd’s official album page states that Roger Waters had left the band before David Gilmour and Nick Mason reconvened and lists “The Dogs of War” on the 1987 album; the licensed Apple Music page credits David Gilmour and Anthony Moore as songwriters. ↩︎
- 17 U.S.C. § 107; U.S. Copyright Office, Fair Use Index and More Information on Fair Use. Section 107 identifies criticism and comment as illustrative purposes for which fair use may apply and requires consideration of purpose and character, the nature of the copyrighted work, the amount and substantiality used, and market effect. The Copyright Office states that fair use is case-specific and has no fixed safe number of words, lines, pages, or percentage. ↩︎
- Mass General Brigham (MGB), “Leadership and Governance” and fiscal year 2024 (FY2024) Form 990; Thermo Fisher Scientific (Thermo Fisher), 2026 proxy statement; Fisher Scientific International Inc., 2006 proxy statement; Brigham and Women’s Hospital (BWH), fiscal year 2009 (FY2009) Form 990; Partners HealthCare System, Inc. (Partners), fiscal year 2014 (FY2014) parent Form 990 and FY2014 affiliates-group Form 990; Thomas H. Lee Partners (THL), Scott Sperling biography. The records document Scott Sperling’s and Marc Casper’s present offices and the transaction-era Board-service pattern; they do not identify Sperling’s or Casper’s participation in a particular selection, review, vote, or recusal. ↩︎
- Thermo Fisher Scientific (Thermo Fisher), 2026 proxy statement. The proxy reports Marc Casper’s 2025 summary-compensation total and conditional retention award, Scott Sperling’s 2025 director compensation and separate Fisher legacy retirement benefit, and the Compensation Committee letter signed by Sperling. Stock-award figures use grant-date accounting values rather than cash realized in 2025. ↩︎
- Mass General Brigham (MGB), “Leadership and Governance” and fiscal year 2024 (FY2024) Form 990. The records report a “business relationship” between Scott Sperling and Marc Casper, identify Anne Klibanski as President and Chief Executive Officer (CEO) and a Director, and describe MGB’s general conflict-disclosure review by the Chairman and President and CEO with assistance from the Office of the General Counsel; they supply no matter-specific review, recusal, or alternate-reviewer record for a disclosure involving the Chairman. ↩︎
- Mass General Brigham (MGB), Cash Balance Program Summary Plan Description; MGB, fiscal years 2025 (FY2025) and 2024 (FY2024) audited financial statements; MGB Employee Retirement Income Security Act of 1974 (ERISA) Master Trust, 2025 Form 5500. The plan description assigns professional-manager selection to MGB’s Board, while the audited statements assign pension oversight and external-manager selection to the Board Investment Committee; the public records do not identify a current authoritative committee roster or matter-specific conduct. ↩︎
- Jonathan Bowen, “The 37 Connectors”. The public companion counts each bounded relationship record or family once, preserves the legal entity and acquisition date, and separates public proof from unanswered terms. ↩︎
- Massachusetts General Hospital (MGH) Laboratory of Computer Science, “50th Anniversary” and Octo Barnett biography. The institutional history identifies the hospital-information-system purpose of the Massachusetts General Hospital Utility Multi-Programming System (MUMPS) and its public-domain release. ↩︎
- InterSystems Corporation (InterSystems), Phillip “Terry” Ragon biography and InterSystems-hosted founder profile; Mass General Brigham (MGB), “Leadership and Governance” and fiscal year 2024 (FY2024) Form 990. The records document Ragon’s Massachusetts General Hospital Utility Multi-Programming System (MUMPS) and InterSystems chronology, current MGB Board service, and the reported InterSystems products-and-services transaction; they do not identify a transfer of MUMPS from Massachusetts General Hospital (MGH) to InterSystems. ↩︎
- Invitrogen, ProQuest Pre-made cDNA Libraries Instruction Manual and Interaction Trap System Manual; Thermo Fisher Scientific (Thermo Fisher), “Completes Acquisition of Life Technologies Corporation”, February 3rd, 2014. The manuals document biological material originating at Massachusetts General Hospital (MGH) and patent-license families predating Thermo Fisher’s acquisition; public terms do not disclose consideration, continuing royalties, or inventor allocations. ↩︎
- Mass General Brigham (MGB), “Urine Test to Detect Kidney Transplant Rejection”; Bio-Techne, “Exclusive Development and License Agreement”; Thermo Fisher Scientific (Thermo Fisher), One Lambda Exosomes Kidney Transplant Assay. The records trace the ExoTRU development-and-commercialization route without publishing the complete agreement, consideration, inventor distribution, or laboratory allocation. ↩︎
- Thermo Electron Corporation, 2002 Partners HealthCare (Partners) collaboration announcement, October 18th, 2002. The announcement identifies four ProteomeX systems, an applications scientist in residence, and direct researcher feedback for product development; it does not price either party’s contribution. ↩︎
- Thermo Electron Corporation, 2004 Massachusetts General Hospital (MGH) biomarker-research announcement, October 26th, 2004. The announcement identifies the Biomarker Research Initiatives in Mass Spectrometry (BRIMS) participants and contributions without supplying the executed agreement or value-allocation terms. ↩︎
- Celia Henry Arnaud, “Inside Instrumentation”, Chemical & Engineering News, July 9th, 2007. The article describes Biomarker Research Initiatives in Mass Spectrometry (BRIMS) as a Thermo Fisher Scientific (Thermo Fisher) technology showcase, identifies company staffing and product development, and reports that the Massachusetts General Hospital (MGH) relationship had ended; it does not disclose MGH’s economics or the termination terms. ↩︎
- Brigham and Women’s Hospital (BWH), fiscal year 2009 (FY2009) Form 990; Partners HealthCare System, Inc. (Partners), parent Forms 990 for fiscal year 2012 (FY2012), fiscal year 2013 (FY2013), and fiscal year 2014 (FY2014). The returns document separately reported products transactions; they do not function as vendor ledgers or support a consolidated grand total. ↩︎
- Brigham and Women’s Hospital (BWH), Department of Pathology Resident Manual; The Journal of Applied Laboratory Medicine, BWH COVID-19 Laboratory Workflow; Mass General Brigham (MGB), Biobank Genomics Core Genotyping; Massachusetts General Hospital (MGH), Haas Lab; Fisher Scientific, “Fisher Scientific Contract Highlights”. The records identify installed platforms, laboratory workflows, and the preferred-provider channel without supplying a complete vendor ledger, bid file, or cumulative spend. ↩︎
- Partners HealthCare System (Partners), federal single audits for fiscal year 2013 (FY2013), fiscal year 2014 (FY2014), fiscal year 2015 (FY2015), and fiscal year 2017 (FY2017); National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) AIDS Reagent Program Notice; Thermo Fisher Scientific (Thermo Fisher), “Completes Acquisition of PPD”, December 8th, 2021. The audits document pass-through infrastructure, while the acquisition record establishes present ownership without making Thermo Fisher the historical counterparty. ↩︎
- Massachusetts General Hospital (MGH), Neuroimmunology Clinic; Thermo Fisher Scientific (Thermo Fisher), “Completes Acquisition of CorEvitas”, August 14th, 2023. The records document a current MGH registry relationship and present Thermo Fisher ownership without supplying funding, data-rights, contract, or initial-participation terms. ↩︎
- ClinicalTrials.gov, NCT01919801, NCT02533180, NCT03644667, NCT04998851, NCT06052059, and NCT07015996. The study records place PPD Development in sponsor or collaborator infrastructure with Massachusetts General Hospital (MGH) or Brigham and Women’s Hospital (BWH); they do not establish hospital selection, payment, data ownership, or one bilateral agreement. ↩︎
- Mass General Brigham (MGB), fiscal years 2025 (FY2025) and 2024 (FY2024) audited financial statements; MGB Employee Retirement Income Security Act of 1974 (ERISA) Master Trust, 2025 Form 5500. The records report different investment pools and measures; their figures remain separate even where Board Investment Committee oversight reaches both. ↩︎
- Thermo Fisher Scientific (Thermo Fisher), 2008 proxy statement. The proxy discloses the Fisher Scientific International Inc. Defined Benefit Master Trust commitments, approximate manager fees and carried interest, Michael Bell’s indirect participation, and Thermo Fisher’s stated related-person-policy treatment; it does not establish any identity with a Mass General Brigham (MGB) trust or decision. ↩︎
- U.S. Department of Labor, Employee Benefits Security Administration (EBSA), “About EBSA”, “Investigative Authority”, and “Subpoenas”. The agency records identify EBSA’s Employee Retirement Income Security Act of 1974 (ERISA) enforcement, investigative, and compulsory-process authority. ↩︎
You must be logged in to post a comment.